NR1D1 and obesity due to melanocortin 4 receptor deficiency: Due to its role in direct modulation of clock and metabolic genes, REV-ERBα is first proposed as a drug target for treating sleep disorders and metabolic syndromes (e.g., dyslipidaemia, hyperglycaemia and obesity) in 2012 7.